vadimezan has been researched along with isogentisin in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (isogentisin) | Trials (isogentisin) | Recent Studies (post-2010) (isogentisin) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 10 | 0 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J; Zhang, L | 1 |
1 other study(ies) available for vadimezan and isogentisin
| Article | Year |
|---|---|
Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
Topics: Antineoplastic Agents; Apoptosis; Hep G2 Cells; Humans; Liver Neoplasms; Nitrates; Nitric Oxide Donors; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Structure-Activity Relationship; Tumor Suppressor Protein p53; Xanthones | 2018 |